Arcturus Stock Based Compensation from 2010 to 2025

ARCT Stock

USD 16.56 0.50 3.11%

Arcturus Therapeutics Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2012-06-30

Previous Quarter

9.4 M

Current Value

9.5 M

Quarterly Volatility

3.6 M

Yuan Drop

Covid

Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 530 K or Selling General Administrative of 63.8 M, as well as many indicators such as Price To Sales Ratio of 4.55, Dividend Yield of 0.0 or PTB Ratio of 2.85. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.

Check out the analysis of Arcturus Therapeutics Correlation against competitors.

Latest Arcturus Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Arcturus Therapeutics Holdings over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Arcturus Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Arcturus Stock Based Compensation Regression Statistics

	Arithmetic Mean	12,603,814
	Geometric Mean	4,004,444
	Coefficient Of Variation	127.31
	Mean Deviation	14,105,119
	Median	2,500,000
	Standard Deviation	16,045,570
	Sample Variance	257.5T
	Range	41.8M
	R-Value	0.85
	Mean Square Error	78.6T
	R-Squared	0.72
	Significance	0.000037
	Slope	2,849,857
	Total Sum of Squares	3861.9T

Arcturus Stock Based Compensation History

	2025	41.8 M
	2024	39.8 M
	2023	34.6 M
	2022	30.6 M
	2021	28.9 M
	2020	6.8 M
	2019	2 M

Other Fundumenentals of Arcturus Therapeutics

Stock Based Compensation To Revenue

Arcturus Therapeutics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Investments	Current Deferred Revenue	Short Long Term Debt	Net Invested Capital	Net Working Capital	Long Term Debt	Long Term Debt Total	Capital Stock	Deferred Long Term Liab
Total Assets		0.98	-0.93	-0.92	0.81	0.7	0.94	1.0	-0.26	0.48	0.95	0.83	0.97	-0.65	0.9	0.83	0.95	0.95	0.88	0.88	-0.87	0.63
Total Stockholder Equity	0.98		-0.95	-0.84	0.79	0.66	0.86	0.99	-0.26	0.39	0.98	0.75	0.94	-0.6	0.84	0.75	0.96	0.96	0.79	0.79	-0.83	0.52
Net Debt	-0.93	-0.95		0.8	-0.92	-0.45	-0.82	-0.95	0.26	-0.5	-0.96	-0.6	-0.89	0.61	-0.73	-0.61	-0.98	-0.97	-0.7	-0.7	0.85	-0.44
Retained Earnings	-0.92	-0.84	0.8		-0.71	-0.71	-0.97	-0.9	0.26	-0.56	-0.77	-0.87	-0.91	0.63	-0.94	-0.89	-0.84	-0.83	-0.96	-0.96	0.83	-0.83
Accounts Payable	0.81	0.79	-0.92	-0.71		0.28	0.76	0.83	-0.18	0.5	0.81	0.45	0.74	-0.71	0.62	0.45	0.88	0.86	0.61	0.61	-0.89	0.4
Net Receivables	0.7	0.66	-0.45	-0.71	0.28		0.72	0.68	-0.15	-0.02	0.56	0.87	0.72	-0.44	0.87	0.87	0.51	0.56	0.8	0.8	-0.56	0.67
Total Liab	0.94	0.86	-0.82	-0.97	0.76	0.72		0.93	-0.23	0.58	0.8	0.89	0.93	-0.67	0.94	0.91	0.85	0.83	0.97	0.97	-0.88	0.8
Total Current Assets	1.0	0.99	-0.95	-0.9	0.83	0.68	0.93		-0.26	0.47	0.96	0.8	0.97	-0.65	0.89	0.8	0.96	0.96	0.86	0.86	-0.87	0.61
Common Stock	-0.26	-0.26	0.26	0.26	-0.18	-0.15	-0.23	-0.26		-0.16	-0.33	-0.23	-0.39	-0.3	-0.25	-0.23	-0.31	-0.31	-0.28	-0.28	0.37	-0.2
Short Term Debt	0.48	0.39	-0.5	-0.56	0.5	-0.02	0.58	0.47	-0.16		0.37	0.45	0.47	-0.32	0.33	0.47	0.52	0.42	0.51	0.51	-0.46	0.5
Net Tangible Assets	0.95	0.98	-0.96	-0.77	0.81	0.56	0.8	0.96	-0.33	0.37		0.65	0.93	-0.5	0.77	0.66	0.96	0.97	0.72	0.72	-0.8	0.43
Property Plant Equipment	0.83	0.75	-0.6	-0.87	0.45	0.87	0.89	0.8	-0.23	0.45	0.65		0.84	-0.53	0.9	0.99	0.67	0.67	0.93	0.93	-0.72	0.8
Capital Surpluse	0.97	0.94	-0.89	-0.91	0.74	0.72	0.93	0.97	-0.39	0.47	0.93	0.84		-0.49	0.93	0.86	0.92	0.92	0.91	0.91	-0.83	0.69
Long Term Investments	-0.65	-0.6	0.61	0.63	-0.71	-0.44	-0.67	-0.65	-0.3	-0.32	-0.5	-0.53	-0.49		-0.58	-0.5	-0.58	-0.58	-0.56	-0.56	0.68	-0.4
Current Deferred Revenue	0.9	0.84	-0.73	-0.94	0.62	0.87	0.94	0.89	-0.25	0.33	0.77	0.9	0.93	-0.58		0.92	0.77	0.79	0.97	0.97	-0.79	0.81
Short Long Term Debt	0.83	0.75	-0.61	-0.89	0.45	0.87	0.91	0.8	-0.23	0.47	0.66	0.99	0.86	-0.5	0.92		0.69	0.68	0.95	0.95	-0.69	0.83
Net Invested Capital	0.95	0.96	-0.98	-0.84	0.88	0.51	0.85	0.96	-0.31	0.52	0.96	0.67	0.92	-0.58	0.77	0.69		0.99	0.76	0.76	-0.85	0.55
Net Working Capital	0.95	0.96	-0.97	-0.83	0.86	0.56	0.83	0.96	-0.31	0.42	0.97	0.67	0.92	-0.58	0.79	0.68	0.99		0.75	0.75	-0.85	0.55
Long Term Debt	0.88	0.79	-0.7	-0.96	0.61	0.8	0.97	0.86	-0.28	0.51	0.72	0.93	0.91	-0.56	0.97	0.95	0.76	0.75		1.0	-0.79	0.87
Long Term Debt Total	0.88	0.79	-0.7	-0.96	0.61	0.8	0.97	0.86	-0.28	0.51	0.72	0.93	0.91	-0.56	0.97	0.95	0.76	0.75	1.0		-0.79	0.87
Capital Stock	-0.87	-0.83	0.85	0.83	-0.89	-0.56	-0.88	-0.87	0.37	-0.46	-0.8	-0.72	-0.83	0.68	-0.79	-0.69	-0.85	-0.85	-0.79	-0.79		-0.58
Deferred Long Term Liab	0.63	0.52	-0.44	-0.83	0.4	0.67	0.8	0.61	-0.2	0.5	0.43	0.8	0.69	-0.4	0.81	0.83	0.55	0.55	0.87	0.87	-0.58

Click cells to compare fundamentals

About Arcturus Therapeutics Financial Statements

Arcturus Therapeutics shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	39.8 M	41.8 M
Stock Based Compensation To Revenue	0.20	0.38

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arcturus Stock Based Compensation from 2010 to 2025

Latest Arcturus Therapeutics' Stock Based Compensation Growth Pattern

Arcturus Stock Based Compensation Regression Statistics

Arcturus Stock Based Compensation History

Other Fundumenentals of Arcturus Therapeutics

Arcturus Therapeutics Stock Based Compensation component correlations

About Arcturus Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Arcturus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY